64
Participants
Start Date
March 9, 2023
Primary Completion Date
March 19, 2023
Study Completion Date
March 19, 2023
RHN-001 (one tablet 750mg)
Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
RHN-001 (750mg * 2 Tablets)
Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS, Karachi
Center for Bioequivalence Studies and Clinical Research
OTHER
RH Nanopharmaceuticals
INDUSTRY